ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0736

Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics

Juan Vargas1, Ian Mantel2, Nirmal Banda1, Anna Helena Jonsson3, Kevin Wei4, Deepak Rao3, Susan Goodman5, Kevin Deane1, The Accelerating Medicines Partnership SLE/RA1, Jennifer Anolik6, Michael Brenner4, Soumya Raychaudhuri3, Jennifer Seifert7, Michael Holer1, Laura Donlin5 and Fan Zhang8, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2Weill Cornell Medicine, New York, NY, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Hospital for Special Surgery, New York, NY, 6University of Rochester Medical Center, Rochester, NY, 7the Accelerating Medicines Partnership (AMP) RA/SLE Network, Boston, MA, 8University of Colorado, Aurora, CO

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, complement, genomics, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Genetics, Genomics & Proteomics

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in autoimmune disease pathogenesis. In patients with rheumatoid arthritis (RA), complement activation proteins generated in the synovium can interact with macrophages and other cell types. However, it remains to be determined how complement components directly modulate cell-type functions in the RA synovium to influence phagocytosis and inflammation resolution.

Methods: We have classified the spectrum of RA biopsies into six tissue phenotypes called CTAPs (Cell Type Abundance Phenotypes) using a comprehensive synovial single-cell multimodal atlas ( >314,000 cells, 28 treatment naïve, 27 Methotrexate and 15 TNF inadequate responders) generated from the AMP RA/SLE (1). In this current study, we linked single-cell transcriptomics of complement activation pathway components and receptors with cell-type heterogeneity and tested significant associations with different tissue phenotypes using unsupervised clustering and network analysis. Next, we characterized myeloid cell differentiation using single-cell trajectory analysis and aligned complement gene expression to myeloid functional states. Furthermore, we utilized cell-type interactome analysis to explore whether complement-dependent receptor-ligand pairs are likely to contribute to tissue pathology.

Results: We generated a complement cellular graph characterizing interactions between complement components and cell-type patterns in RA synovium. The complement components present unexpected distinct transcriptomic expression across cell types (Figure 1A). We next systematically captured the relationship between tissue phenotypes with specific complement gene expression (Figure 1B). Within myeloid cells, we identified a myeloid cell differentiation axis revealing that functional macrophage modules align with complement pathways; in particular, complement FCN1 and CFP co-vary with the IL1B+ pro-inflammatory macrophages (p < 2e-16; R=0.48), while complement C1QA-C and C3AR1 co-vary with the MERTK+ phagocytic macrophages (p < 2e-16; R=0.7) (Figure 2). Intriguingly, we revealed that the abundance of complement-dependent receptor-ligand (C3AR1-C3 and C5AR2-C5) are correlated across patients (Figure 3A), and interactome analysis further suggests a potential interaction between the C3AR1 highly expressed MERTK+ macrophages and C3 highly expressed sublining fibroblasts in a particular RA synovial phenotype that relatively lacks lymphocytes (Figure 3B).

Conclusion: Through systematically aligning complement pathways with synovial heterogeneity, we generated a graph describing how complement components can modulate functional cells, especially macrophage phenotypes, in stratified RA patients. This approach of analyzing high-resolution single-cell data in human synovium brings insights into complement pathway-based targets and mechanisms to evaluate in patients with RA, and provides a roadmap for other complex pathways in tissues.

References.
1. Zhang, F. et al. Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis. bioRxiv 2022 doi:10.1101/2022.02.25.481990.

Supporting image 1

Fig. 1. Single-cell expression distributions of complement components across cell types in rheumatoid arthritis synovial tissues (A). Different myeloid, fibroblast and endothelial cell states express different complement components. Relationship between complement components and RA synovial tissue phenotypes (B).

Supporting image 2

Fig. 2. Myeloid-specific single-cell trajectory analysis revealed a myeloid cell differentiation trajectory from phagocytic to pro-inflammatory lineage. Complement components C1QA-B, C3AR1, and C2 expressions correlated with anti-inflammatory/phagocytic functions (A); complement components FCN1 and CFP expressions correlated with pro-inflammatory function (B). Spearman correlation R and p-value are shown.

Supporting image 3

Fig. 3. Across cell type analyses revealed complement-development receptor-ligand correlations (A) and potential complement pathway-dependent C3+ sublininig fibroblasts and MERTK+ tissue macrophages interacting patterns in stratified RA tissues (B). Spearman correlation and p-value are shown.


Disclosures: J. Vargas: None; I. Mantel: None; N. Banda: None; A. Jonsson: None; K. Wei: 10X Genomics, 5, capital one, 6, Gilead sciences, 5, horizon therapeutics, 6, Mestag, 2; D. Rao: AstraZeneca, 2, Bristol-Myers Squibb, 2, 5, GlaxoSmithKlein(GSK), 2, Hifibio, 2, Janssen, 5, Merck, 5, Scipher Medicine, 2; S. Goodman: NIH, 5, Novartis, 5; K. Deane: Bristol-Myers Squibb(BMS), 1, Gilead, 5, Janssen, 5, Werfen, 1, 12, Biomarker kits; J. Seifert: None; J. Anolik: None; M. Brenner: 4FO Ventures, 2, GlaxoSmithKlein(GSK), 2, Mestag Therapeutics, 2, 11, Third Rock Ventures, 2; S. Raychaudhuri: AbbVie, 6, Janssen, 1, Mestag, Inc, 2, 8, Pfizer, 1, Sanofi, 1, Sonoma, 1, 8; A. Network: None; M. Holer: None; L. Donlin: Bristol-Myers Squibb(BMS), 2, Stryker, 2; F. Zhang: None.

To cite this abstract in AMA style:

Vargas J, Mantel I, Banda N, Jonsson A, Wei K, Rao D, Goodman S, Deane K, Seifert J, Anolik J, Brenner M, Raychaudhuri S, Network A, Holer M, Donlin L, Zhang F. Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/deciphering-complement-system-dependent-cellular-pathways-in-human-rheumatoid-arthritis-synovial-tissue-using-large-single-cell-computational-omics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deciphering-complement-system-dependent-cellular-pathways-in-human-rheumatoid-arthritis-synovial-tissue-using-large-single-cell-computational-omics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology